Efficacy of antiviral therapy based on sorfosbuvir combination in the treatment of patients with hepatitis C-induced liver cirrhosis
Objective The aim of this study was to investigate clinical efficacy of antiviral therapy based on sorfosbuvir(SOF)combination in the treatment of patients with hepatitis C-induced liver cirrhosis(LC).Methods 39 patients with chronic hepatitis C-related compensated liver cirrhosis(CHC-CLC)and 23 patients with CHC-related decompensated liver cirrhosis(CHC-DLC)were encountered in our hospital between July 2019 and December 2022,and SOF and verapamil(VEL)combination was given in patients with CHC-CLC,and SOF and verapamil(VEL)combination plus ribavirin was given in patients with CHC-DLC for 12 weeks.Serum HCV RNA loads,biochemical index and routine blood cell counts were detected,and aspartate transaminase(AST)/platelet(PLT)ratio index(APRI)and fibrosis 4 score(FIB-4)were calculated.Liver stiffness measurement(LSM)was detected by Fibroscan.Results By end of treatment,two patients(8.7％)with CHC-DLC died;of survivals,early virologic response,end of treatment virologic response,sustained virologic response at 24 weeks(SVR 24)and SVR 48 in patients with CHC-CLC were 92.3％,100.0％,100.0％and 100.0％,all much superior to 80.9％,100.0％,76.2％and 66.7％(P＜0.05)in patients with CHC-DLC;by end of antiviral treatment,peripheral blood platelet count and serum albumin level in patients with CHC-CLC were(140.6±26.3)×109/L and(36.4±1.8)g/L,both significantly higher than[(70.5±27.0)×109/L and(33.4±2.7)g/L,respectively,P＜0.05]in patients with CHC-DLC;APRI,FIB-4 and LSM in patients with CHC-CLC were(1.1±0.4),(3.0±1.0)and(13.8±2.0)kPa,all significantly lower than[(1.7±0.7),(5.1± 1.7)and(26.2±2.5)kPa,respectively,P＜0.05]in patients with CHC-DLC.Conclusion DA As therapy based on SOF has an satisfactory virological response in patients with CHC-CLC or CHC-DLC,with improved biochemical parameters,while the long-term efficacy needs further clinical observation.
国家科技期刊平台
NSTL
万方数据
维普
